Tags

Type your tag names separated by a space and hit enter

Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.
Can Med Assoc J. 1973 Oct 06; 109(7):588-93.CM

Abstract

A dual study was conducted to assess (1) the long-term antiparkinsonian action of amantadine without levodopa and (2) the advantage of combined amantadine and levodopa over single-drug therapy, including changes in symptom severity when placebo replaces amantadine but levodopa is maintained.Good to excellent results were obtained in 25% of the total pool of 77 patients on amantadine. No decline in therapeutic effect took place during a mean follow-up of 21 months.Thirty-seven patients with considerable residual deficit after single-drug therapy derived improvement from the second drug (levodopa or amantadine). Gains in neurological signs and activities of daily living (ADL) ranged between 50 and 60% and for timed skills close to 25%. Depending on the individual indices, between 64 and 100% of patients improved with the second drug.Placebo instead of amantadine produced deterioration. There was 75% loss in ADL, 45% loss in timed skills and losses in neurological signs exceeded gains produced by two-drug therapy.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

4582563

Citation

Zeldowicz, L R., and J Hubermann. "Long-term Therapy of Parkinson's Disease With Amantadine, Alone and Combined With Levodopa." Canadian Medical Association Journal, vol. 109, no. 7, 1973, pp. 588-93.
Zeldowicz LR, Hubermann J. Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa. Can Med Assoc J. 1973;109(7):588-93.
Zeldowicz, L. R., & Hubermann, J. (1973). Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa. Canadian Medical Association Journal, 109(7), 588-93.
Zeldowicz LR, Hubermann J. Long-term Therapy of Parkinson's Disease With Amantadine, Alone and Combined With Levodopa. Can Med Assoc J. 1973 Oct 6;109(7):588-93. PubMed PMID: 4582563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa. AU - Zeldowicz,L R, AU - Hubermann,J, PY - 1973/10/6/pubmed PY - 1973/10/6/medline PY - 1973/10/6/entrez SP - 588 EP - 93 JF - Canadian Medical Association journal JO - Can Med Assoc J VL - 109 IS - 7 N2 - A dual study was conducted to assess (1) the long-term antiparkinsonian action of amantadine without levodopa and (2) the advantage of combined amantadine and levodopa over single-drug therapy, including changes in symptom severity when placebo replaces amantadine but levodopa is maintained.Good to excellent results were obtained in 25% of the total pool of 77 patients on amantadine. No decline in therapeutic effect took place during a mean follow-up of 21 months.Thirty-seven patients with considerable residual deficit after single-drug therapy derived improvement from the second drug (levodopa or amantadine). Gains in neurological signs and activities of daily living (ADL) ranged between 50 and 60% and for timed skills close to 25%. Depending on the individual indices, between 64 and 100% of patients improved with the second drug.Placebo instead of amantadine produced deterioration. There was 75% loss in ADL, 45% loss in timed skills and losses in neurological signs exceeded gains produced by two-drug therapy. SN - 0008-4409 UR - https://www.unboundmedicine.com/medline/citation/4582563/Long_term_therapy_of_Parkinson's_disease_with_amantadine_alone_and_combined_with_levodopa_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/4582563/ DB - PRIME DP - Unbound Medicine ER -